AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 36428089 — intervention group
Group type: EXPERIMENTAL
Intervention: SB intervention
Number of subjects: 564
Study 36428089 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined group
Number of subjects: 564
Study 36428089 — intervention group
Group type: EXPERIMENTAL
Intervention: Blood parameters
Number of subjects: 564
Study 36654481 — intervention group
Group type: EXPERIMENTAL
Intervention: Concentrated pomegranate juice (PJ) 45 ml/day
Number of subjects: 44
Study 36654481 — intervention group
Group type: COMPARATOR
Intervention: Control group without intervention
Number of subjects: 44
Study 33472675 — intervention group
Group type: EXPERIMENTAL
Intervention: C1 esterase/kallikrein inhibitor 20 U/kg intravenously on day 1 and day 4 plus standard care
Number of subjects: 180
Study 33472675 — intervention group
Group type: EXPERIMENTAL
Intervention: Icatibant 30 mg subcutaneously, three doses/day for 4 days plus standard care
Number of subjects: 180
Study 33472675 — intervention group
Group type: COMPARATOR
Intervention: Standard care alone
Number of subjects: 180
Study 36156313 — intervention group
Group type: EXPERIMENTAL
Intervention: Photodynamic therapy (PDT)
Number of subjects: 39
Study 36156313 — intervention group
Group type: EXPERIMENTAL
Intervention: High-power diode laser (DL)
Number of subjects: 39
Study 36156313 — intervention group
Group type: COMPARATOR
Intervention: Control group (standard chemo-mechanical treatment)
Number of subjects: 39
Study 33357677 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (Ca) at levels of 2.68%
Number of subjects: 30
Study 33357677 — intervention group
Group type: EXPERIMENTAL
Intervention: Available phosphorus (aP) at levels of 0.38%
Number of subjects: 30
Study 33357677 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (Ca) levels increased linearly
Number of subjects: 30
Study 33357677 — intervention group
Group type: EXPERIMENTAL
Intervention: Calcium (Ca) levels
Number of subjects: 30
Study 33357677 — intervention group
Group type: EXPERIMENTAL
Intervention: Daily feed intake (DFI)
Number of subjects: 30
Study 33357677 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone density (BD) and bone resistance (BR)
Number of subjects: 30
Study 33357677 — intervention group
Group type: EXPERIMENTAL
Intervention: Bone resistance (BR) of the femur
Number of subjects: 30
Study 33357677 — intervention group
Group type: EXPERIMENTAL
Intervention: Feed conversion ratio per egg dozen
Number of subjects: 30
Study 32753043 — intervention group
Group type: EXPERIMENTAL
Intervention: Multidirectional stitching technology
Number of subjects: 40
Study 32753043 — intervention group
Group type: COMPARATOR
Intervention: Traditional suture method
Number of subjects: 40
Study 34808036 — intervention group
Group type: EXPERIMENTAL
Intervention: 3.7 g day-1 n-3 fatty acids (fish oil)
Number of subjects: 20
Study 34808036 — intervention group
Group type: EXPERIMENTAL
Intervention: 200 mg fenofibrate
Number of subjects: 20
Study 34808036 — intervention group
Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 20
Study 32804248 — intervention group
Group type: EXPERIMENTAL
Intervention: Locking plates
Number of subjects: 60
Study 32804248 — intervention group
Group type: COMPARATOR
Intervention: Nonlocking plates
Number of subjects: 60
Study 35396307 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone (LDN) 4.5 mg once daily for 12 weeks
Number of subjects: 122
Study 35396307 — intervention group
Group type: COMPARATOR
Intervention: Placebo for 12 weeks
Number of subjects: 122
Study 35396307 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose naltrexone (LDN)
Number of subjects: 122
Study 35396307 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 122
Study 33822748 — intervention group
Group type: EXPERIMENTAL
Intervention: Pornographic videos
Number of subjects: 74
Study 33822748 — intervention group
Group type: EXPERIMENTAL
Intervention: Pornographic cues
Number of subjects: 74
Study 33822748 — intervention group
Group type: COMPARATOR
Intervention: Control videos
Number of subjects: 74
Study 33822748 — intervention group
Group type: COMPARATOR
Intervention: Control cues
Number of subjects: 74
Study 32540922 — intervention group
Group type: EXPERIMENTAL
Intervention: Substantial decrease in HbA1c (≥10%)
Number of subjects: 8576
Study 32540922 — intervention group
Group type: EXPERIMENTAL
Intervention: Substantial increase in HbA1c (≥10%)
Number of subjects: 8576
Study 32540922 — intervention group
Group type: EXPERIMENTAL
Intervention: Greater long-term variability in HbA1c (per 1 SD of ASV)
Number of subjects: 8576
Study 34120223 — intervention group
Group type: EXPERIMENTAL
Intervention: T-DM1 3.6 mg/kg IV every 3 weeks × 17
Number of subjects: 123
Study 34120223 — intervention group
Group type: COMPARATOR
Intervention: Paclitaxel (T) 80 mg/m2 with trastuzumab (H) IV qw × 12 (4 mg/kg load → 2 mg/kg), followed by H (6 mg/kg IV q3w × 13)
Number of subjects: 123
Study 32538009 — intervention group
Group type: EXPERIMENTAL
Intervention: Filiform fire needling
Number of subjects: 66
Study 32538009 — intervention group
Group type: COMPARATOR
Intervention: Oral analgesics (bucinnazine hydrochloride and oxycodone hydrochloride)
Number of subjects: 66
Study 36315066 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-delivered pain management program
Number of subjects: 1333
Study 36315066 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 1333
Study 33416043 — intervention group
Group type: EXPERIMENTAL
Intervention: Online psychoeducation and peer support for adult carers
Number of subjects: 407
Study 32941439 — intervention group
Group type: EXPERIMENTAL
Intervention: Message valence (empathic accurate response) and modality (with emojis)
Number of subjects: 160
Study 32941439 — intervention group
Group type: EXPERIMENTAL
Intervention: Synchronicity (immediate response)
Number of subjects: 160
Study 32941439 — intervention group
Group type: EXPERIMENTAL
Intervention: Social presence
Number of subjects: 160
Study 32941439 — intervention group
Group type: EXPERIMENTAL
Intervention: Subjective social presence
Number of subjects: 160
Study 32941439 — intervention group
Group type: EXPERIMENTAL
Intervention: Perceived and subjective social presence
Number of subjects: 160
Study 36502317 — intervention group
Group type: EXPERIMENTAL
Intervention: Remote Expressive Arts Program (rEAP)
Number of subjects: 73
Study 36502317 — intervention group
Group type: COMPARATOR
Intervention: Health Education (HE)
Number of subjects: 73
Study 33901161 — intervention group
Group type: EXPERIMENTAL
Intervention: Blue-enriched white light
Number of subjects: 48
Study 33901161 — intervention group
Group type: COMPARATOR
Intervention: Conventional light
Number of subjects: 48
Study 34855001 — intervention group
Group type: EXPERIMENTAL
Intervention: Abbreviated total spine MRI protocol (IRsag + T2ax)
Number of subjects: 206
Study 34855001 — intervention group
Group type: COMPARATOR
Intervention: Standard non-contrast MRI protocol
Number of subjects: 206
Study 33095994 — intervention group
Group type: EXPERIMENTAL
Intervention: noninvasive high-frequency oscillatory ventilation (nHFOV)
Number of subjects: 30
Study 33095994 — intervention group
Group type: COMPARATOR
Intervention: nasal continuous positive airway pressure (nCPAP)
Number of subjects: 30
Study 32131518 — intervention group
Group type: EXPERIMENTAL
Intervention: 20 mM oleic acid (OA) mouth rinse
Number of subjects: 31
Study 32131518 — intervention group
Group type: COMPARATOR
Intervention: Control mouth rinse
Number of subjects: 31
Study 35132545 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking-focused, proactive coaching intervention (6 telephone coaching sessions over 8-14 weeks)
Number of subjects: 380
Study 35132545 — intervention group
Group type: EXPERIMENTAL
Intervention: Walking-focused, proactive coaching intervention
Number of subjects: 380
Study 35132545 — intervention group
Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 380
Study 33908343 — intervention group
Group type: EXPERIMENTAL
Intervention: Internet-based cognitive behavioral therapy for insomnia (ICBT-I)
Number of subjects: 136630
Study 33908343 — intervention group
Group type: COMPARATOR
Intervention: Usual-care arm (in-person classes on insomnia)
Number of subjects: 136630
Study 34863046 — intervention group
Group type: EXPERIMENTAL
Intervention: Mediterranean diet (Med)
Number of subjects: 183
Study 34863046 — intervention group
Group type: COMPARATOR
Intervention: Low-fat diet (LF)
Number of subjects: 183
Study 34490711 — intervention group
Group type: EXPERIMENTAL
Intervention: Rhythmic eye movements during virtual reality exposure therapy (VRET)
Number of subjects: 53
Study 34490711 — intervention group
Group type: COMPARATOR
Intervention: Control group undergoing exposure without rhythmic eye movements
Number of subjects: 53
Study 32037380 — intervention group
Group type: EXPERIMENTAL
Intervention: Diuretic
Number of subjects: 57
Study 32037380 — intervention group
Group type: EXPERIMENTAL
Intervention: Nitrate
Number of subjects: 57
Study 32037380 — intervention group
Group type: EXPERIMENTAL
Intervention: Lifestyle modification
Number of subjects: 57
Study 34750450 — intervention group
Group type: EXPERIMENTAL
Intervention: Neutral bicarbonate ionized water (NBIW)
Number of subjects: 0
Study 34750450 — intervention group
Group type: COMPARATOR
Intervention: Control solution
Number of subjects: 0
Study 35437246 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal exercise intervention (balance programmes and walking programme delivered by physiotherapists over 6 months)
Number of subjects: 396
Study 35437246 — intervention group
Group type: COMPARATOR
Intervention: Usual care (control group)
Number of subjects: 396
Study 35437246 — intervention group
Group type: EXPERIMENTAL
Intervention: Multimodal exercise intervention
Number of subjects: 396
Study 33546755 — intervention group
Group type: EXPERIMENTAL
Intervention: CT-P17
Number of subjects: 648
Study 33546755 — intervention group
Group type: COMPARATOR
Intervention: EU-adalimumab
Number of subjects: 648
Study 32294883 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple Polyphenol (AP) 300 mg/day
Number of subjects: 65
Study 32294883 — intervention group
Group type: EXPERIMENTAL
Intervention: Apple Polyphenol (AP) 600 mg/day
Number of subjects: 65
Study 32294883 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 65
Study 35581106 — intervention group
Group type: EXPERIMENTAL
Intervention: Cardamom inhalation therapy
Number of subjects: 70
Study 35581106 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 70
Study 33313814 — intervention group
Group type: COMPARATOR
Intervention: CHW intervention
Number of subjects: 0
Study 33313814 — intervention group
Group type: COMPARATOR
Intervention: CHW + CCT intervention
Number of subjects: 0
Study 33313814 — intervention group
Group type: EXPERIMENTAL
Intervention: Control
Number of subjects: 0
Study 33225972 — intervention group
Group type: EXPERIMENTAL
Intervention: Assisted by two midwives during the second stage of labour
Number of subjects: 2946
Study 33225972 — intervention group
Group type: COMPARATOR
Intervention: Assisted by one midwife during the second stage of labour
Number of subjects: 2946
Study 33225972 — intervention group
Group type: EXPERIMENTAL
Intervention: Two midwives intervention
Number of subjects: 2946
Study 33225972 — intervention group
Group type: EXPERIMENTAL
Intervention: Questionnaires sent at 1 month and 1 year post-birth
Number of subjects: 2946
Study 35979852 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents in all cultural categories (Marginalization, Integration, Separation, Assimilation)
Number of subjects: 280
Study 35979852 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents in Integration and Assimilation
Number of subjects: 280
Study 35979852 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents in Integration
Number of subjects: 280
Study 35979852 — intervention group
Group type: EXPERIMENTAL
Intervention: Adolescents in Marginalization, Integration, and Assimilation
Number of subjects: 280
Study 35979852 — intervention group
Group type: EXPERIMENTAL
Intervention: Parents across all acculturation categories
Number of subjects: 280
Study 35979852 — intervention group
Group type: EXPERIMENTAL
Intervention: Participants (both parents and adolescents)
Number of subjects: 280
Study 34288956 — intervention group
Group type: EXPERIMENTAL
Intervention: Substance use (smoking, drug use, alcohol consumption)
Number of subjects: 424
Study 34288956 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk factors for substance use
Number of subjects: 424
Study 32859329 — intervention group
Group type: EXPERIMENTAL
Intervention: Synbiotic (Bacillus coagulans plus inulin)
Number of subjects: 53
Study 32859329 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 53
Study 36451448 — intervention group
Group type: EXPERIMENTAL
Intervention: 3D printing technology + PBL method
Number of subjects: 269
Study 36451448 — intervention group
Group type: COMPARATOR
Intervention: Traditional teaching methods
Number of subjects: 269
Study 34102020 — intervention group
Group type: EXPERIMENTAL
Intervention: UC-MSCs (1×10^6 /kg body weight in 100ml saline)
Number of subjects: 40
Study 34102020 — intervention group
Group type: COMPARATOR
Intervention: Control (100ml 0.9% saline)
Number of subjects: 40
Study 32428747 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS and risperidone plus family intervention (combined group)
Number of subjects: 200
Study 32428747 — intervention group
Group type: EXPERIMENTAL
Intervention: rTMS and risperidone
Number of subjects: 200
Study 32428747 — intervention group
Group type: EXPERIMENTAL
Intervention: family intervention and risperidone
Number of subjects: 200
Study 32428747 — intervention group
Group type: EXPERIMENTAL
Intervention: risperidone alone (risperidone group)
Number of subjects: 200
Study 32428747 — intervention group
Group type: COMPARATOR
Intervention: Control group (risperidone only)
Number of subjects: 200
Study 35132052 — intervention group
Group type: EXPERIMENTAL
Intervention: CT scan
Number of subjects: 1010
Study 35132052 — intervention group
Group type: EXPERIMENTAL
Intervention: PET scan
Number of subjects: 1010
Study 35132052 — intervention group
Group type: EXPERIMENTAL
Intervention: Total thyroidectomy followed by LDLT
Number of subjects: 1010
Study 35977248 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-integrated access to the Minnesota PDMP
Number of subjects: 309
Study 35977248 — intervention group
Group type: COMPARATOR
Intervention: Usual access to PDMP via web portal
Number of subjects: 309
Study 35977248 — intervention group
Group type: EXPERIMENTAL
Intervention: EHR-integrated PDMP tool
Number of subjects: 309
Study 35977248 — intervention group
Group type: COMPARATOR
Intervention: Web-based and delegate queries
Number of subjects: 309
Study 33580692 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactononadecapeptide (LNDP) tablets
Number of subjects: 0
Study 33580692 — intervention group
Group type: COMPARATOR
Intervention: Placebo tablets
Number of subjects: 0
Study 35200335 — intervention group
Group type: EXPERIMENTAL
Intervention: Smartwatch-based sensor for sleep quantification
Number of subjects: 38
Study 35200335 — intervention group
Group type: COMPARATOR
Intervention: Smartwatch-based sensor for sleep quantification with clonazepam
Number of subjects: 38
Study 33390422 — intervention group
Group type: EXPERIMENTAL
Intervention: Mealtime fast-acting insulin aspart
Number of subjects: 245
Study 33390422 — intervention group
Group type: EXPERIMENTAL
Intervention: Post-meal fast-acting insulin aspart
Number of subjects: 245
Study 33390422 — intervention group
Group type: COMPARATOR
Intervention: Insulin aspart
Number of subjects: 245
Study 32575103 — intervention group
Group type: EXPERIMENTAL
Intervention: Clary sage aromatherapy
Number of subjects: 79
Study 32575103 — intervention group
Group type: EXPERIMENTAL
Intervention: Lavender aromatherapy
Number of subjects: 79
Study 32575103 — intervention group
Group type: COMPARATOR
Intervention: Control group
Number of subjects: 79
Study 36129696 — intervention group
Group type: EXPERIMENTAL
Intervention: Complete revascularization (additional PCI of angiographically significant nonculprit lesions)
Number of subjects: 4041
Study 36129696 — intervention group
Group type: COMPARATOR
Intervention: Culprit lesion-only PCI
Number of subjects: 4041
Study 32898346 — intervention group
Group type: EXPERIMENTAL
Intervention: Reminder-Focused Positive Psychiatry (RFPP)
Number of subjects: 11
Study 32898346 — intervention group
Group type: COMPARATOR
Intervention: Trauma-Focused Cognitive-Behavioral Therapy (TF-CBT)
Number of subjects: 11
Study 32926418 — intervention group
Group type: EXPERIMENTAL
Intervention: 450 mg Valganciclovir (VGCV) daily
Number of subjects: 70
Study 32926418 — intervention group
Group type: EXPERIMENTAL
Intervention: 900 mg Valganciclovir (VGCV) daily
Number of subjects: 70
Study 32926418 — intervention group
Group type: EXPERIMENTAL
Intervention: Sampling strategies of plasma concentrations at 0 and 2 hours and 0, 2, and 4 hours after VGCV administration
Number of subjects: 70
Study 32926418 — intervention group
Group type: EXPERIMENTAL
Intervention: Clearance of creatinine
Number of subjects: 70
Study 32690032 — intervention group
Group type: EXPERIMENTAL
Intervention: Sequentially combined tDCS with MT (SEQ)
Number of subjects: 28
Study 32690032 — intervention group
Group type: COMPARATOR
Intervention: Concurrently combined tDCS with MT (CON)
Number of subjects: 28
Study 32690032 — intervention group
Group type: COMPARATOR
Intervention: Sham tDCS with MT (SHAM)
Number of subjects: 28
Study 34391078 — intervention group
Group type: EXPERIMENTAL
Intervention: 12-min sub-maximal fitness test on a cycle ergometer
Number of subjects: 117
Study 34391078 — intervention group
Group type: EXPERIMENTAL
Intervention: Higher pre-exercise cravings
Number of subjects: 117
Study 34391078 — intervention group
Group type: EXPERIMENTAL
Intervention: Lower cardiorespiratory fitness
Number of subjects: 117
Study 32521890 — intervention group
Group type: EXPERIMENTAL
Intervention: Sorafenib combined with TACE
Number of subjects: 118
Study 32521890 — intervention group
Group type: COMPARATOR
Intervention: TACE
Number of subjects: 118
Study 34454788 — intervention group
Group type: EXPERIMENTAL
Intervention: Rotavirus vaccine (RV) with routine EPI vaccines
Number of subjects: 142
Study 32183265 — intervention group
Group type: EXPERIMENTAL
Intervention: Grafting material applied during sinus floor elevation (test group)
Number of subjects: 49
Study 32183265 — intervention group
Group type: COMPARATOR
Intervention: No graft applied during sinus floor elevation (control group)
Number of subjects: 49
Study 36448844 — intervention group
Group type: EXPERIMENTAL
Intervention: Telephone-delivered intervention for alcohol use problems
Number of subjects: 344
Study 32686552 — intervention group
Group type: EXPERIMENTAL
Intervention: Biogenetic lecture
Number of subjects: 280
Study 32686552 — intervention group
Group type: COMPARATOR
Intervention: Control lecture
Number of subjects: 280
Study 33207993 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Enteral Nutrition (PEN) - casein-based formula for 12 months providing 25% of estimated daily energy requirements
Number of subjects: 34
Study 33207993 — intervention group
Group type: EXPERIMENTAL
Intervention: Partial Enteral Nutrition (PEN)
Number of subjects: 34
Study 33207993 — intervention group
Group type: COMPARATOR
Intervention: Non-PEN (control group)
Number of subjects: 34
Study 32215208 — intervention group
Group type: EXPERIMENTAL
Intervention: β-carotene supplementation
Number of subjects: 29133
Study 32215208 — intervention group
Group type: COMPARATOR
Intervention: Dietary vitamin C intake, fruit and vegetable intake
Number of subjects: 29133
Study 32215208 — intervention group
Group type: COMPARATOR
Intervention: Vitamin E supplementation
Number of subjects: 29133
Study 35657656 — intervention group
Group type: EXPERIMENTAL
Intervention: CHOICE trial intervention (PC-based alcohol care management)
Number of subjects: 27
Study 33196153 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous evinacumab 450 mg weekly
Number of subjects: 272
Study 33196153 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous evinacumab 300 mg weekly
Number of subjects: 272
Study 33196153 — intervention group
Group type: EXPERIMENTAL
Intervention: Subcutaneous evinacumab 300 mg every 2 weeks
Number of subjects: 272
Study 33196153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous evinacumab 15 mg/kg every 4 weeks
Number of subjects: 272
Study 33196153 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous evinacumab 5 mg/kg every 4 weeks
Number of subjects: 272
Study 33196153 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 272
Study 33651448 — intervention group
Group type: EXPERIMENTAL
Intervention: Poor control of HDLC, LDLC, blood pressure, and HbA1c
Number of subjects: 2500
Study 33651448 — intervention group
Group type: EXPERIMENTAL
Intervention: Drinking
Number of subjects: 2500
Study 32883723 — intervention group
Group type: EXPERIMENTAL
Intervention: Online cognitive-behavioural therapy (CBT)
Number of subjects: 0
Study 32883723 — intervention group
Group type: COMPARATOR
Intervention: Waitlist control
Number of subjects: 0
Study 34981621 — intervention group
Group type: EXPERIMENTAL
Intervention: Biocon's Insulin‐R
Number of subjects: 42
Study 34981621 — intervention group
Group type: COMPARATOR
Intervention: Humulin‐R
Number of subjects: 42
Study 33861011 — intervention group
Group type: EXPERIMENTAL
Intervention: Commercial skin protection products
Number of subjects: 6
Study 33861011 — intervention group
Group type: COMPARATOR
Intervention: Control (untreated)
Number of subjects: 6
Study 32826011 — intervention group
Group type: EXPERIMENTAL
Intervention: Lumbopelvic manipulation (LPM)
Number of subjects: 44
Study 32826011 — intervention group
Group type: COMPARATOR
Intervention: Sham Lumbopelvic manipulation (positioning with no thrust)
Number of subjects: 44
Study 32345092 — intervention group
Group type: EXPERIMENTAL
Intervention: Victimization-focused prevention tips (n = 114)
Number of subjects: 321
Study 32345092 — intervention group
Group type: EXPERIMENTAL
Intervention: Perpetration-focused prevention tips (n = 103)
Number of subjects: 321
Study 32345092 — intervention group
Group type: COMPARATOR
Intervention: Study tips for control purposes (n = 104)
Number of subjects: 321
Study 34376188 — intervention group
Group type: EXPERIMENTAL
Intervention: Home-based dialogical intervention
Number of subjects: 22
Study 35190972 — intervention group
Group type: EXPERIMENTAL
Intervention: QLHER2 (test) at single doses escalating from 0.2 to 6 mg/kg
Number of subjects: 76
Study 35190972 — intervention group
Group type: EXPERIMENTAL
Intervention: QLHER2
Number of subjects: 76
Study 35190972 — intervention group
Group type: COMPARATOR
Intervention: Herceptin (reference) at 4 mg/kg
Number of subjects: 76
Study 33137340 — intervention group
Group type: COMPARATOR
Intervention: EOS789 50 mg
Number of subjects: 20
Study 33137340 — intervention group
Group type: EXPERIMENTAL
Intervention: EOS789 100 mg
Number of subjects: 20
Study 33137340 — intervention group
Group type: COMPARATOR
Intervention: EOS789 100 mg plus 1600 mg sevelamer
Number of subjects: 20